Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma
NCT06673628Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2024
- Primary completion
- Nov 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in cutaneous angiosarcoma (cAS), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall Response Rate by central review up to 1 year. Started Dec 2024; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
cutaneous angiosarcoma (cAS)
Beyond the preview
Go deeper on NCT06673628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673628.